Investing.com - Catalyst Pharmaceuticals reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Catalyst Pharmaceuticals announced earnings per share of $0.260 on revenue of $57.2M. Analysts polled by Investing.com anticipated EPS of $0.180 on revenue of $53.62M.
Catalyst Pharmaceuticals shares are up 4.35% from the beginning of the year, still down 15.74% from its 52 week high of $17.22 set on September 13.
Catalyst Pharmaceuticals follows other major Healthcare sector earnings this month
Catalyst Pharmaceuticals's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar